Dr. Ku on Combinations and Sequencing of Treatments for Gastric Cancer

Geoffrey Y. Ku, MD
Published: Monday, Jan 23, 2017



Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combinations and sequencing of treatments for patients with gastric and esophageal cancers.

Patients getting the treatment in the third-line setting is too late, explains Ku. There are 10 other phase III studies that are evaluating treatment in the first- and second-line setting.

Another area of improvement is biomarker selection. Up until this point, the main biomarker has been PD-L1 expression on the tumor cells; however, it’s not perfect, Ku states. When PD-L1 is used as a biomarker, PD-L1–positive tumors respond approximately 25% of the time, whereas PD-L1–negative tumors respond 10% of the time.
 
SELECTED
LANGUAGE


Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combinations and sequencing of treatments for patients with gastric and esophageal cancers.

Patients getting the treatment in the third-line setting is too late, explains Ku. There are 10 other phase III studies that are evaluating treatment in the first- and second-line setting.

Another area of improvement is biomarker selection. Up until this point, the main biomarker has been PD-L1 expression on the tumor cells; however, it’s not perfect, Ku states. When PD-L1 is used as a biomarker, PD-L1–positive tumors respond approximately 25% of the time, whereas PD-L1–negative tumors respond 10% of the time.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x